Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
  • English
    • 日本語
Evaluate Logo

navigation

  • What We Do
  • Vantage
    • News
    • Analysis
    • Policy & Pricing
    • Data Insights
    • Events
    • Medtech
    • Therapy Areas
    • About Vantage
      • Editorial team
  • Products & Services
    • Consensus Forecasts
    • Pharma
      • EvaluatePharma
      • EvaluatePharma Vision
    • Custom Solutions
    • How We Can Help You
      • Pharma and Biotech
      • Medtech
      • Financial Services
      • Management Consultancies
      • Service Providers
    • Client Success
    • Customer Testimonials
  • Thought Leadership
    • English
    • 日本語
  • About Us
    • Media Centre
      • Press Releases
      • Media Coverage
    • Executive Team
    • Vision & History
  • Careers
    • Current Vacancies
  • Contact Us
  • Sign Up for Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Policy & Pricing
    • Policy & Regulation
    • Pricing
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Kura Oncology

Thumbnail
October 24, 2018

Esmo 2018 – Adaptimmune gets the wooden spoon

The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.

Thumbnail
August 14, 2018

Most valuable unpartnered assets reveal a changing of the guard

Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.

Article image
Vantage logo
August 22, 2017

The sector’s most valuable unpartnered assets – up for grabs or on the shelf?

Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?

Article image
Vantage logo
August 16, 2017

Biogen’s Alzheimer’s hope tops the sector’s most valuable pipeline projects

The lack of clinical progress in Alzheimer's has not put analysts off valuing aducanumab at $10bn.

Vantage logo
March 13, 2015

J&J re-homes cancer project with Kura

We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 31, 2019

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

February 26, 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

View more...

Editor's Picks

Vantage logo
October 22, 2019

Shock revelation sees Biogen erase its aducanumab losses

Vantage logo
October 22, 2019

Vertex’s double cystic fibrosis surprise

Vantage logo
October 23, 2019

Bristol might play a role in front-line lung cancer after all

Vantage logo
October 23, 2019

Bloated on arrival? Biotech's weightiest new issues

Vantage logo
October 14, 2019

Uncovering biopharma’s hidden treasures

Open modal

Evaluate HQ +44-(0)20-7377-0800

Evaluate Americas +1-617-573-9450

Evaluate APAC +81 (0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

Follow Us

© Copyright 2019 Evaluate Ltd.